IP Library Granted Patent US 10,206,960
Granted Patent B2
US 10,206,960 · App. 13/637,817 · Granted Feb 19, 2019

Stabilisation of viral particles

Inventors: Jeffrey Drew (London, GB); David Woodward (London, GB); John Bainbridge (London, GB); Amanda Corteyn (London, GB)
Assignee: Stabilitech Biopharma Ltd
A61K35/76C12N7/00A61K9/19A61K39/00A61K47/183A61K47/20A61K47/26C12N2710/10351
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,206,960
App. No.
13/637,817
Granted
Feb 19, 2019
Kind
B2
Abstract

A method for preserving viral particles comprising: (a) providing an aqueous solution of (i) viral particles, (ii) optionally one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating said viral particles.

Claims (36)

1. A method for preserving live viral particles during freeze-drying, the method comprising:

(a) preparing an aqueous solution, which is optionally buffered, the solution comprising:

(i) live viral particles selected from Adenoviridae, Orthomyxoviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Poxviridae, Calciviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Papillomaviridae, Reoviridae, Retroviridae, and Toqaviridae, and

(ii) as the sole excipients one or more sugars at a total sugar concentration of 0.1 M to 3M, 0.1 to 1.5M of N,N-dimethylglycine or a physiologically acceptable salt or ester thereof, and 0.1 to 1.5M of methylsulfonylmethane;

and

(b) freeze-drying the solution prepared in step (a) to form a composition incorporating said live viral particles.

2. The method according to claim 1 in which the sugar concentration of the aqueous solution is 0.2M to 2M.

3. The method according to claim 1 wherein aqueous solution comprises sucrose and one or more other sugar(s), and the ratio of the concentration of sucrose relative to the other sugar(s) is from 1:1 to 20:1 and/or the other sugar is raffinose.

4. The method according to claim 1 wherein one sugar is present which is mannitol.

5. A method of preparing a vaccine which incorporates live viral particles that are preserved during freeze-drying, which method comprises:

(a) preparing an aqueous solution, which is optionally buffered, the solution comprising:

(i) live viral particles selected from Adenoviridae, Orthomyxoviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Poxviridae, Calciviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Papillomaviridae, Reoviridae, Retroviridae, and Togaviridae, and

(ii) as the sole excipients one or more sugars at a total sugar concentration of 0.1 M to 3M, 0.1 to 1.5M of N,N-dimethylglycine or a physiologically acceptable salt or ester thereof, and 0.1 to 1.5M of methylsulfonylmethane;

and

(b) optionally adding an adjuvant, buffer, antibiotic and/or additive to the aqueous solution of (a); and

(c) freeze-drying the solution prepared in step (a) or (b) to form a solid composition incorporating said live viral particles.

6. A method for preserving live viral particles during freeze-drying, the method comprising:

(a) preparing an aqueous solution which consists of:

(i) live viral particles selected from Adenoviridae, Orthornyxoviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Poxviridae, Calciviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Papillomaviridae, Reoviridae, Retroviridae, and Togaviridae,

(ii) one or more sugars at a total sugar concentration of 0.1M to 3M,

(iii) 0.1 to 1.5M of N,N-dimethylglycine or a physiologically acceptable salt or ester thereof,

(iv) 0.1 to 1.5M of methylsulfonylmethane;

(iv) optionally one or more buffers;

and

(b) freeze-drying the solution prepared in step (a) to form a composition incorporating said live viral particles.

7. A method of preparing a vaccine which incorporates live viral particles that are preserved during freeze-drying, which method comprises:

(a) preparing an aqueous solution, which is optionally buffered, and consists of (i) live viral particles selected from Adenoviridae, Orthomyxoviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Poxviridae, Calciviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Papillornaviridae, Reoviridae, Retroviridae, and Toqaviridae, (ii) one or more sugars at a total sugar concentration of 0.1M to 3M, (iii) 0.1 to 1.5M of N,N-dimethylglycine or a physiologically acceptable salt or ester thereof, and (iv) 0.1 to 1.5M of methylsulfonylmethane;

and

(b) optionally adding an adjuvant, buffer, antibiotic and/or additive to the aqueous solution of (a); and

(c) freeze-drying the solution prepared in step (a) or (b) to form a composition or solid composition incorporating said live viral particles.

8. The method according to claim 1 in which two sugars are present which are sucrose and raffinose.

9. The method according to claim 8 in which the ratio of the concentration of sucrose relative to raffinose is from 1:1 to 20:1.

10. The method according to claim 1 in which the viral particles are composed of a live virus which is a whole virus or live-attenuated virus.

11. The method according to claim 1 in which the aqueous solution comprises viral particles selected from Adenoviridae, Orthomyxoviridae, Paramyxoviridae, Parvoviridae, Picornoviridae and Poxviridae.

12. The method according to claim 11 in which the aqueous solution comprises viral particles selected from an adenovirus, vaccinia virus, influenza virus and measles virus.

13. The method according to claim 1 in which the aqueous solution comprises viral particles from Adenoviridae.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2021
From: STABILITECH BIOPHARMA LTD
To: IOSBIO LTD
Reel/Frame 056065/0883 →
CHANGE OF NAME Recorded Jun 19, 2018
From: STABILITECH LTD.
To: STABILITECH BIOPHARMA LTD
Reel/Frame 046129/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2013
From: DREW, JEFFREY; WOODWARD, DAVID; BAINBRIDGE, JOHN; CORTEYN, AMANDA
To: STABILITECH LTD.
Reel/Frame 029654/0617 →
Priority Claims (7)
EP 10250706 · Mar 31, 2010 · regional
GB 1005497.1 · Mar 31, 2010 · national
GB 1005520.0 · Mar 31, 2010 · national
GB 1005521.8 · Mar 31, 2010 · national
GB 1014962.3 · Sep 8, 2010 · national
GB 1017647.7 · Oct 19, 2010 · national
GB 1017648.5 · Oct 19, 2010 · national
Continuity (1)
Related Publication 20130129685A1 · May 23, 2013